Company Overview and News
MCLEAN, Va., July 10, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (the “Company”) announced today that its board of directors declared the following monthly cash distributions to preferred and common stockholders and also announced its plan to report earnings for the first fiscal quarter ended June 30, 2018.
GAIN GAINM GADDP
Sabre Corp. said Monday Doug Barnett will join the company as chief financial officer, effective July 23. He will succeed Rick Simonson, who announced plans to retire in January, after five years with online travel services company. Barnett was most recently CFO of cloud data management company Informatica. Sabre's stock, which was still inactive in premarket trade, has run up 20% year to date, while the S&P 500 has gained 1.
BL ECOM GAIN GAINM MOMO JAG GADDP SABR
Though shares sell for a premium to NAV, Golub Capital is a solid choice for income investors in the BDC sector, in my opinion.
GSBD AIY AINV GBDC MAIN GAIN GAINM AIB GADDP HTGX PSEC HTGY HTGZ MSCA.CL MSCA HTGC PBB
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Trade battles are set to dominate another week's action, with a set of hair-trigger responses from former trade allies leading world news though threatened tariffs are still small in the face of a $20T U.
CTRV STZ.B GIS GAIN WBA MS.PRE PS MS.PRF MS.PRG MS.PRA NKE NSM NTRS TWTR CAG MS SONC AKAO AKAM CBAY GWP BAC TMUS SBHMY CCL STZ VTIQU CMG GWPH MS.PRI MS.PRK WMIH VTIQ NTRA QCOM PRGS MNKD WFCNP NTRSP RAD MCK WFC.PRL GAINM WFC.PRJ PIR TEP GADDP TEGP BAC WFC.PRT GS ATRC WFC.PRR WFC.PRQ LEA WFC.PRP BIIB WFC.PRO FII WFC.PRN MKC AAPL CCL HEI ACN WFC.PRY WFC.PRX BIDU WFC.PRW DRRX BBBY DIS WFC.PRV PAYX WFC WFC.WS C MD CMCSA COOL PTIE SNX SRE.PRA BLK S SBKO JPM SRE SNE INFO TMCX
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSI MSCA.CL OCSL MCX TRI NEWTL PBB
MCLEAN, Va., June 15, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (the "Company") announced today that it plans to hold a conference call on Tuesday, June 26, 2018, at 9:00 am EDT to discuss the matters scheduled for a vote at this year's annual meeting of stockholders to be held on August 2, 2018. On Friday, June 15, 2018, the Company filed its proxy statement for the annual meeting of stockholders (the "Proxy Statement") with the U.
GAIN GAINM GADDP
Following continued requests from readers, this article first performs a FMV investing rating analysis on TSLX’s portfolio companies over the prior four quarters.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX JIVE NEWTL PBB
This article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB
Following multiple requests by readers, this article analyzes TSLX’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX NEWTL PBB
MCLEAN, Va., June 04, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (“Gladstone Investment”) announced today the sale of its equity interest and the prepayment of its debt investments in Drew Foam Companies, Inc. (“Drew Foam”) to a private equity firm. As a result of this transaction, Gladstone Investment realized a significant gain on its equity investment.
GAIN GAINM GADDP
Following multiple requests, this article analyzes GAIN’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP MSCA TSLX NEWT MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB
Good day, ladies and gentlemen, and welcome to the Gladstone Investment Corporation Fourth Quarter and Year Ended 03/31/2018 Earnings Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] And as a reminder, this conference call is being recorded.
GAIN GAINM GADDP
This article assesses MAIN’s performance for Q1 2018 and compares results over the trailing twelve months.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX CVOVQ CVO NEWTL PBB
MCLEAN, Va., May 01, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (“Gladstone Investment”) announced today that on April 4, 2018, Gladstone Investment partnered with Bassett Creek Capital, Inc. (“BCC”) to form Bassett Creek Restoration, Inc. (“Bassett Creek Restoration”), a platform for acquiring and integrating restoration and renovation companies across the United States.
GAIN GAINM GADDP
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
as of ET